A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

Completed · Phase 2

Conditions studied: Melanoma

In brief

A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.

Key facts

Study ID

NCT00281541

Run by

Astellas Pharma Inc

People needed

29

Starts

2005-11-01

Expected to finish

2007-06-01

Last updated by the study team

2012-06-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed unresectable stage III or IV malignant melanoma
• Life expectancy >12 weeks

You may not qualify if…

• History of other malignancy in the last 5 years
• Major surgery within the past 21 days

Where it is running

• Study site — Tuscon, Arizona, United States
• Study site — Little Rock, Arkansas, United States
• Study site — Aurora, Colorado, United States
• Study site — Washington D.C., District of Columbia, United States
• Study site — Atlanta, Georgia, United States
• Study site — Montclair, New Jersey, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Pittsburgh, Pennsylvania, United States
• Study site — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.